Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies

Nuvectis Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.

Joseph Pantginis has given his Buy rating due to a combination of factors related to Nuvectis Pharma’s ongoing clinical studies and the promising potential of their lead candidate, NXP900. The company’s recent initiation of the Phase 1b study assessing NXP900 in combination with osimertinib represents a significant milestone, targeting patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) who have developed resistance to current standards of care. The broad enrollment criteria, which do not require specific genetic alterations, enhance the study’s scope and patient accessibility.
Additionally, NXP900 has demonstrated promising safety and efficacy signs in Phase 1a, including potent suppression of resistance pathways such as SRC inhibition. Combining NXP900 with established targeted therapies like osimertinib and lorlatinib addresses a critical unmet need in reversing or delaying treatment resistance, an area with no approved options. These factors, coupled with expected data readouts in 2026 that could provide meaningful efficacy signals, underline the positive outlook for Nuvectis Pharma’s stock and support Pantginis’s Buy rating.